TY - JOUR AU - Caselli, Gianfranco AU - Bonazzi, Albino AU - Lanza, Marco AU - Ferrari, Flora AU - Maggioni, Daniele AU - Ferioli, Cristian AU - Giambelli, Roberto AU - Comi, Eleonora AU - Zerbi, Silvia AU - Perrella, Marco AU - Letari, Ornella AU - Di Luccio, Elena AU - Colovic, Milena AU - Persiani, Stefano AU - Zanelli, Tiziano AU - Mennuni, Laura AU - Piepoli, Tiziana AU - Rovati, Lucio Claudio PY - 2018 DA - 2018/03/01 TI - Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug JO - Arthritis Research & Therapy SP - 39 VL - 20 IS - 1 AB - Prostaglandin E2 (PGE2) acts via its EP4 receptor as a cytokine amplifier (e.g., interleukin [IL]-6) and induces the differentiation and expansion of inflammatory T-helper (Th) lymphocytes. These mechanisms play a key role in the onset and progression of rheumatoid arthritis (RA). We present the pharmacological characterisation of CR6086, a novel EP4 receptor antagonist, and provide evidence for its potential as a disease-modifying anti-rheumatic drug (DMARD). SN - 1478-6362 UR - https://doi.org/10.1186/s13075-018-1537-8 DO - 10.1186/s13075-018-1537-8 ID - Caselli2018 ER -